JOURNAL OF HUMAN HYPERTENSION, a prominent publication in the field of internal medicine, is dedicated to advancing the understanding of hypertension and its implications for human health. Published by SPRINGERNATURE in the United Kingdom, this esteemed journal has been a vital resource for researchers and clinicians since its inception in 1987, with a continuous commitment to disseminating high-quality, peer-reviewed research. With an impressive Q2 category rank in Internal Medicine and a Scopus rank of 53 out of 167, it occupies a crucial position within the academic community, reaching a 68th percentile ranking that underscores its significance. The journal aims to provide a platform for innovative studies and reviews, fostering knowledge that bridges basic science, clinical practice, and public health. Although it does not currently offer open access, it remains accessible through institutional subscriptions, ensuring that vital information about hypertension is available to a broad spectrum of healthcare professionals and researchers. Explore the critical findings and groundbreaking research published in the JOURNAL OF HUMAN HYPERTENSION to stay at the forefront of hypertension studies.

Cardiovascular Diagnosis and Therapy, an esteemed journal in the field of Cardiology and Cardiovascular Medicine, is published by AME PUBLISHING COMPANY, based in Hong Kong, China. With an ISSN of 2223-3652 and an E-ISSN of 2223-3660, this open-access journal aims to present cutting-edge research that significantly advances diagnostic and therapeutic practices in cardiovascular health. Recognized for its impact, it holds a 2023 category quartile ranking of Q2 and is positioned at rank #124 out of 387 in Scopus, reflecting its noteworthy contribution to medical literature with a percentile of 68th. The journal welcomes contributions that span various aspects of cardiovascular research, including clinical trials, epidemiological studies, and innovative therapeutic approaches, making it a vital resource for researchers, practitioners, and students alike, committed to improving cardiovascular care.

Current Hypertension Reviews, published by Bentham Science Publishers Ltd, stands as a leading journal in the field of internal medicine, particularly focusing on hypertension and related cardiovascular disorders. With an impressive impact factor and ranked #59 out of 167 in the Scopus medicine category, this journal highlights key insights and contemporary research trends from its inception in 2006 to 2024. Its commitment to making high-quality research accessible to the medical community, despite lacking an Open Access option, ensures that it continues to contribute significantly to the scientific discourse surrounding hypertension management and innovative treatments. Researchers, clinicians, and students alike will find valuable resources within its pages, as Current Hypertension Reviews plays a critical role in advancing the understanding and treatment of hypertension, ultimately supporting better health outcomes globally.

Netherlands Heart Journal is a premier academic publication dedicated to advancing knowledge in the field of cardiology and cardiovascular medicine. Published by BOHN STAFLEU VAN LOGHUM BV, this journal has established itself as a critical platform for researchers, professionals, and students seeking to explore groundbreaking findings and innovative practices in cardiovascular health. With an ISSN of 1568-5888 and E-ISSN 1876-6250, the journal boasts a respectable Q2 ranking in the Cardiology and Cardiovascular Medicine category, placing it in the top half of its field according to the 2023 quartiles. The Scopus ranking places it 130th out of 387 in the relevant category, indicating a commendable percentile rank of 66th, which attests to its influence and quality of published research. Spanning from 2005 to 2024, the journal endeavors to include a diverse array of topics, encompassing clinical practice, technological innovations, and public health considerations related to cardiovascular diseases. Researchers and practitioners are encouraged to engage with the journal's robust content, contributing to and benefiting from the collaborative effort to enhance cardiovascular health worldwide.

Asian Biomedicine, published by WALTER DE GRUYTER GMBH, serves as a crucial platform for disseminating pioneering research in the field of biomedical sciences. Established in 2008, this journal has carved its niche in the landscape of academic publishing, concentrating on a diverse array of topics within biochemistry, genetics, and molecular biology, as well as medicine. Though it currently holds a Q4 ranking in its category, it is dedicated to fostering academic discussions and advancing knowledge among researchers, professionals, and students alike. While the journal features a variety of access options, it is committed to ensuring that its content remains relevant and impactful, with an emphasis on the latest developments and research trends. The editorial board encourages submissions that address pressing biomedical issues, thus empowering contributors to engage meaningfully with the scientific community. With a broad international scope and a focus on quality, Asian Biomedicine is poised to play an increasingly important role in the advancement of biomedical research in Asia and beyond.

Cardiology in Review, published by Lippincott Williams & Wilkins, is a prominent journal focused on advancing the field of cardiology and cardiovascular medicine. With a history of publication spanning from 1995 to 2024, the journal serves as an essential resource for researchers, healthcare professionals, and students alike, offering in-depth reviews and analyses on the latest developments, clinical practices, and research findings in cardiology. Despite being a traditional print journal, it maintains a commendable Q2 ranking in both cardiology and miscellaneous medicine categories as of 2023, reflecting its influence and rigor in the academic community, with a Scopus rank of #132 out of 387 in its field, placing it in the 66th percentile. The journal aims to bridge the gap between clinical practice and emerging research, promoting a deeper understanding and integration of innovative strategies in cardiovascular care. With its commitment to high-quality scholarship, Cardiology in Review remains a vital conduit for knowledge and dialogue within the evolving landscape of cardiovascular health.

Clinica e Investigacion en Arteriosclerosis is a premier academic journal dedicated to the field of cardiology and cardiovascular medicine, published by ELSEVIER. With its ISSN 0214-9168 and E-ISSN 1578-1879, the journal aims to disseminate high-quality research and innovations in the understanding and treatment of arterial diseases, contributing significantly to both clinical practices and pharmacological advancements. Established in 2007 and continuing into 2024, the journal has garnered recognition with a notable Q3 categorization in both Cardiology and Cardiovascular Medicine and Pharmacology (medical) for 2023, reflecting its impact in the academic community. Researchers and healthcare professionals utilizing this journal will find a diverse range of articles exploring novel therapeutic strategies and epidemiological data, making it an essential resource for advancing knowledge and practice in cardiovascular health. While it does not operate as an open-access journal, the findings published in Clinica e Investigacion en Arteriosclerosis are pivotal for understanding current trends and future directions in cardiovascular research.

Metabolic Syndrome and Related Disorders is an esteemed journal published by MARY ANN LIEBERT, INC, focusing on the multifaceted aspects of metabolic syndrome, including its interaction with chronic diseases such as diabetes, cardiovascular conditions, and obesity. Since its inception in 2003, this journal has established itself as a vital resource for researchers, healthcare professionals, and students dedicated to advancing knowledge in the fields of endocrinology, internal medicine, and metabolic disorders. With an impact factor reflective of its academic significance, Metabolic Syndrome and Related Disorders is recognized within the Q2 and Q3 quartiles in its respective categories, solidifying its reputation among scientific and clinical communities. Although it does not currently offer open access options, the journal remains committed to disseminating high-quality research and reviews that foster innovative solutions and improve patient outcomes. The journal's gradual convergence towards 2024 presents an exciting opportunity for continued exploration and dialogue about metabolic-related health challenges.

American Journal of Hypertension, published by Oxford University Press, is a leading peer-reviewed journal dedicated to the field of hypertension and cardiovascular health. With an ISSN of 0895-7061 and an E-ISSN of 1941-7225, this prestigious journal has been providing researchers and clinicians with significant advancements in hypertension research since its inception in 1954, with a continued focus on innovative studies through 2024. Ranked Q2 in Internal Medicine and positioned within the top 22% of its category according to Scopus, it is a vital resource for those involved in clinical practice and research aimed at understanding and managing hypertension. The journal disseminates pivotal findings, treatment updates, and guideline recommendations that contribute to improved patient care globally. Accessible solely through subscription, the American Journal of Hypertension is essential reading for professionals committed to enhancing cardiovascular health outcomes.

JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, published by SAGE PUBLICATIONS INC, stands as a vital resource in the fields of Endocrinology and Internal Medicine. With an impressive open access model established in 2014, this journal facilitates broad dissemination of high-quality research that explores the complex mechanisms and clinical implications of the renin-angiotensin-aldosterone system (RAAS). Currently, it is recognized within the 2023 Category Quartiles as Q3 in Endocrinology and Q2 in Internal Medicine, reflecting its significant impact on the scientific community. The journal ranks in the 75th percentile for Internal Medicine and the 57th percentile in Endocrinology according to Scopus, indicating its strong contributions to these disciplines. Covering a rich history from its inception in 2000 to the present, the journal aims to bridge the gap between basic research and clinical practice, thereby enhancing the understanding and treatment of conditions influenced by RAAS. The continuous publication of innovative research makes it an essential reference for researchers, healthcare professionals, and students engaged in these dynamic fields.